

Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC)

**Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer**

**Trial Status**  
Recruiting

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT05954871 2022-502530-10-00  
GO44272

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT05954871 2022-502530-10-00 GO44272**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---